Lhasa Limited shared knowledge shared progress

Webinar - Mirabilis: Controlling potential genotoxic impurities encountered during API synthesis

Burns MJ;

Dr Mike Burns, Scientist at Lhasa, presents on the workings of Mirabilis in relation to assessing risk in accordance with regulatory guidelines.

Controlling potentially mutagenic impurities (PMIs) is a critical part of the development of any pharmaceutical product. The ICH M7 guideline outlines a series of control options that are aligned with risk-based principles. The Mirabilis software has been developed as an industry-standardised in silico tool for the calculation of purge factors of impurities according to the Teasdale approach, led by a cross-industry consortium.

Herein, we present on the development of Mirabilis and describe a theoretical case study which will highlight the process involved when performing a risk assessment aligned to control option 4 for regulatory submission using Mirabilis.




Additional Documents

© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.